一项考察甲状腺癌治疗结局与自身免疫性甲状腺炎存在关系的前瞻性多中心研究
该研究基于意大利甲状腺癌观察站(ITCO)数据库前瞻性纳入4233例分化型甲状腺癌(DTC)患者,其中1552例(36.7%)合并自身免疫性甲状腺炎(AT)。但仅以结构性持续病灶为结局时,两组间无统计学显著差异(3.4% vs 2.7%,p=0.35)。
要点
- 倾向性评分匹配后,AT患者1年疾病证据(结构性/生化不完全反应)比例高于无AT患者(7.3% vs 4.5%)。
- 仅以结构性持续病灶为结局时,AT组与无AT组无统计学显著差异(3.4% vs 2.7%,p=0.35)。
- 诊断时ATA中危和高危风险与结局的关联在各分析中持续存在统计学显著性。
核心结论
- 在这一大型前瞻性系列中,AT患者1年随访时生化持续更常见,但AT的存在与结构性持续病灶无显著关联,作者认为这些发现可能由残留甲状腺组织解释。
研究设计与样本
- 前瞻性多中心研究,纳入意大利甲状腺癌观察站(ITCO)数据库(NCT04031339)连续入组的分化型甲状腺癌(DTC)患者,共4233例,其中女性3172例(75%)。
- 按是否合并自身免疫性甲状腺炎(AT)分为AT组(1552例,36.7%)和无AT组,采用倾向性评分匹配比较两组临床特征及1年随访结局。
主要发现
- ATA危险度分层:低危51%(2160/4233),中危41.3%(1750/4233),高危7.6%(323/4233)。
- 倾向性评分匹配前,AT患者显著更年轻且肿瘤更小、多为双侧(p<0.0001),更多归入低危和中危,而无AT患者中ATA高危更常见(p=0.004)。
- 仅以结构性持续病灶为结局时,AT组与无AT组无统计学显著差异(3.4% vs 2.7%,p=0.35)。
- 诊断时ATA中危和高危风险相关的风险升高在各分析中持续存在统计学显著性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: There is some controversy on the potential relationship between autoimmune processes and clinicopathologic features as well as prognosis of differentiated thyroid cancer (DTC), and the evidence is limited by its largely retrospective nature. We examined the relationship between the presence of autoimmune thyroiditis (AT) and 1-year thyroid cancer treatment outcomes in a large multicenter study using prospectively collected data. Methods: We included data from consecutive DTC patients enrolled in the Italian Thyroid Cancer Observatory (ITCO) database (NCT04031339). We divided the groups according to the presence (AT) or absence (no autoimmune thyroiditis [noAT]) of associated AT. We used propensity score matching to compare the clinical features and outcomes between the two groups at 1-year follow-up. Results: We included data from 4233 DTC patients, including 3172 (75%) females. The American Thyroid Association (ATA) risk levels were as follows: 51% (2160/4233) low risk, 41.3% (1750/4233) intermediate risk, and 7.6% (323/4233) high risk. There were 1552 patients (36.7%) who had AT. Before propensity score matching, AT patients were significantly younger and had a smaller and bilateral tumor (p < 0.0001). Patients with AT more frequently fell into the low- and intermediate-risk categories, while the ATA high risk was more frequent among noAT patients (p = 0.004). After propensity score matching, patients with AT more frequently showed evidence of disease (structural/biochemical incomplete response) versus excellent/indeterminate response, compared with patients without AT (7.3% vs. 4.5%, p = 0.001), with an odds ratio of 1.86 ([confidence interval: 1.3-2.6], p = 0.0001). However, when considering only structural persistence as the outcome, no statistically significant differences were observed between patients with or without AT (3.4% vs. 2.7%, p = 0.35). The elevated risk associated with the ATA intermediate and high risk at diagnosis remained consistently statistically significant. Conclusions: In this large prospective series, biochemical persistence was more frequent, at 1-year follow-up, in AT patients. However, there was no significant association between the presence of AT and structural persistence of disease. These findings may be explained by the presence of a residual thyroid tissue.
引用
- De Leo S, D'Elia S, Grani G, et al. A Prospective Multicenter Study Examining the Relationship Between Thyroid Cancer Treatment Outcomes and the Presence of Autoimmune Thyroiditis. Thyroid. 2023. PMID: 37725571. doi:10.1089/thy.2023.0052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。